Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2012

01-11-2012 | Original Article

The Burden of Untreated Hepatitis C Virus Infection: A US Patients’ Perspective

Authors: Antoine C. El Khoury, Jeffrey Vietri, Girish Prajapati

Published in: Digestive Diseases and Sciences | Issue 11/2012

Login to get access

Abstract

Background

Hepatitis C virus (HCV) infection is widespread and associated with high economic costs and reduced quality of life, but the impact of untreated HCV infection on patient outcome is not well understood.

Aims

To estimate the impact of untreated HCV infection on work productivity, daily activity, healthcare use, economic costs, and health-related quality of life (HRQoL).

Methods

Respondents to the 2010 US National Health and Wellness Survey (n = 75,000) reporting physician diagnosis of HCV infection but not current or previous treatment (patients) were matched to respondents without HCV infection (controls) by use of propensity scores. Those reporting infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) were excluded. Self-reported work impairment, activity impairment, healthcare resource use, and HRQoL were compared between patients and controls. Indirect and direct costs were estimated.

Results

A total of 306 patients met inclusion criteria. Patients were more impaired at work than controls, with overall work impairment of 26 % versus 15 %, respectively (P < 0.001), mostly because of presenteeism in both groups. Annual productivity losses were estimated at $10,316 per employed patient compared with $5,469 per control (P < 0.001). Patients used more healthcare, with all-cause healthcare costs estimated at $22,818 per patient annually, compared with $15,362 per control (P < 0.001). HRQoL and activity impairment were also worse among patients than controls.

Conclusions

Untreated HCV infection is associated with substantial economic costs to society, through loss of productivity and increased use of healthcare resources, and with impaired well-being of the patient.
Literature
1.
go back to reference Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705.PubMedCrossRef Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705.PubMedCrossRef
2.
go back to reference Wang CC, Krantz E, Klarquist J, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474.PubMedCrossRef Wang CC, Krantz E, Klarquist J, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474.PubMedCrossRef
4.
go back to reference McHutchison JG, Bacon BR, Owens GS. Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care. 2007;13:327. McHutchison JG, Bacon BR, Owens GS. Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care. 2007;13:327.
5.
go back to reference Seeff LB, Hoofnagle JH. National Institutes of Health consensus development conference: management of hepatitis C. Hepatology. 2002;36:s1–s2.PubMedCrossRef Seeff LB, Hoofnagle JH. National Institutes of Health consensus development conference: management of hepatitis C. Hepatology. 2002;36:s1–s2.PubMedCrossRef
6.
go back to reference McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care. 2005;11:S286–S295. (quiz S307-211).PubMed McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care. 2005;11:S286–S295. (quiz S307-211).PubMed
7.
go back to reference Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14:107–115.PubMedCrossRef Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14:107–115.PubMedCrossRef
9.
go back to reference Solomon M, Bonafede M, Pan K, et al. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci. 2011;56:3024–3031.PubMedCrossRef Solomon M, Bonafede M, Pan K, et al. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci. 2011;56:3024–3031.PubMedCrossRef
10.
go back to reference Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677.PubMedCrossRef Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677.PubMedCrossRef
11.
go back to reference Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385–389.PubMedCrossRef Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385–389.PubMedCrossRef
12.
go back to reference Brook RA, Kleinman NL, Su J, Corey-Lisle P, Iloeje UH. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care. 2011;17:8. Brook RA, Kleinman NL, Su J, Corey-Lisle P, Iloeje UH. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care. 2011;17:8.
13.
14.
16.
go back to reference Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.PubMedCrossRef Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.PubMedCrossRef
17.
go back to reference McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838.PubMedCrossRef McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838.PubMedCrossRef
18.
go back to reference DiBonaventura M, Wagner JS, Yuan Y, L’Italien G, Langley P, Ray Kim W. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ. 2011;14:253–261.PubMedCrossRef DiBonaventura M, Wagner JS, Yuan Y, L’Italien G, Langley P, Ray Kim W. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ. 2011;14:253–261.PubMedCrossRef
19.
go back to reference Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010;52:436–442.PubMedCrossRef Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010;52:436–442.PubMedCrossRef
20.
go back to reference Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45:e17–e24.PubMedCrossRef Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45:e17–e24.PubMedCrossRef
21.
go back to reference McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther. 2011;33:1268–1280.PubMedCrossRef McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther. 2011;33:1268–1280.PubMedCrossRef
22.
go back to reference Jhaveri R, Grant W, Kauf TL, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr. 2006;148:353–358.PubMedCrossRef Jhaveri R, Grant W, Kauf TL, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr. 2006;148:353–358.PubMedCrossRef
23.
go back to reference Bonkovsky HL, Snow KK, Malet PF, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46:420–431.PubMedCentralPubMedCrossRef Bonkovsky HL, Snow KK, Malet PF, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46:420–431.PubMedCentralPubMedCrossRef
24.
go back to reference DiBonaventura MD, Wagner JS, Yuan Y, L’Italien G, Langley P, Ray Kim W. Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ. 2010;13:709–718.PubMedCrossRef DiBonaventura MD, Wagner JS, Yuan Y, L’Italien G, Langley P, Ray Kim W. Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ. 2010;13:709–718.PubMedCrossRef
25.
go back to reference Foster G, Goldin R, Thomas H. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27:209–212.PubMedCrossRef Foster G, Goldin R, Thomas H. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27:209–212.PubMedCrossRef
26.
go back to reference McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health-related quality of life and work productivity. J Hepatol. 2001;34:140–147.PubMedCrossRef McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health-related quality of life and work productivity. J Hepatol. 2001;34:140–147.PubMedCrossRef
27.
go back to reference Marcellin P, Chousterman M, Fontanges T, et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int. 2011;31:516–524.PubMedCrossRef Marcellin P, Chousterman M, Fontanges T, et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int. 2011;31:516–524.PubMedCrossRef
28.
go back to reference Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health. 2010;13:479–486.PubMedCrossRef Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health. 2010;13:479–486.PubMedCrossRef
29.
go back to reference Ware J, Kosinski M, Turner-Bowker D, Gandek B. SF-12v2: How to Score Version 2 of the SF-12 Health Survey Quality Metric Incorporated. Lincoln, RI: Health Assessment Lab Boston, Massachusetts; 2002. Ware J, Kosinski M, Turner-Bowker D, Gandek B. SF-12v2: How to Score Version 2 of the SF-12 Health Survey Quality Metric Incorporated. Lincoln, RI: Health Assessment Lab Boston, Massachusetts; 2002.
30.
go back to reference Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353.PubMedCrossRef Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353.PubMedCrossRef
31.
go back to reference Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33–38. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33–38.
32.
go back to reference Parsons LS. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Cary NC: SAS Institute Inc.; 2001:214–226. Parsons LS. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Cary NC: SAS Institute Inc.; 2001:214–226.
33.
go back to reference Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22:165–184.PubMedCrossRef Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22:165–184.PubMedCrossRef
34.
go back to reference BLS. Highlights of Women’s Earnings in 2010. Washington, DC: Labor USDo; 2011. BLS. Highlights of Women’s Earnings in 2010. Washington, DC: Labor USDo; 2011.
35.
go back to reference Machlin SR. Expenses for a Hospital Emergency Room Visit, 2003. Rockville, MD: Medical Expenditure Panel Survey, Agency for Healthcare Research and Quality; 2006. Machlin SR. Expenses for a Hospital Emergency Room Visit, 2003. Rockville, MD: Medical Expenditure Panel Survey, Agency for Healthcare Research and Quality; 2006.
36.
go back to reference Ware JE, Kosinski M. SF-36 Physical & Mental Health Summary Scales: A Manual for Users of Version 1. Lincoln, RI: Quality Metric Inc.; 2001. Ware JE, Kosinski M. SF-36 Physical & Mental Health Summary Scales: A Manual for Users of Version 1. Lincoln, RI: Quality Metric Inc.; 2001.
37.
go back to reference Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–292.PubMedCrossRef Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–292.PubMedCrossRef
38.
go back to reference Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33:350–357.PubMedCrossRef Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33:350–357.PubMedCrossRef
39.
go back to reference Farivar SS, Liu H, Hays RD. Half standard deviation estimate of the minimally important difference in HRQOL scores? Expert Rev Pharmacoecon Outcomes Res. 2004;4:515–523.PubMedCrossRef Farivar SS, Liu H, Hays RD. Half standard deviation estimate of the minimally important difference in HRQOL scores? Expert Rev Pharmacoecon Outcomes Res. 2004;4:515–523.PubMedCrossRef
40.
go back to reference Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582.PubMed Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582.PubMed
41.
go back to reference Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523–1532.PubMedCrossRef Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523–1532.PubMedCrossRef
42.
go back to reference Himelhoch S, Mccarthy JF, Ganoczy D, et al. Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. Psychosomatics. 2009;50:30–37.PubMedCentralPubMedCrossRef Himelhoch S, Mccarthy JF, Ganoczy D, et al. Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. Psychosomatics. 2009;50:30–37.PubMedCentralPubMedCrossRef
43.
go back to reference Lerner D, Amick BC 3rd, Lee JC, et al. Relationship of employee-reported work limitations to work productivity. Med Care. 2003;41:649–659.PubMed Lerner D, Amick BC 3rd, Lee JC, et al. Relationship of employee-reported work limitations to work productivity. Med Care. 2003;41:649–659.PubMed
Metadata
Title
The Burden of Untreated Hepatitis C Virus Infection: A US Patients’ Perspective
Authors
Antoine C. El Khoury
Jeffrey Vietri
Girish Prajapati
Publication date
01-11-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2233-1

Other articles of this Issue 11/2012

Digestive Diseases and Sciences 11/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine